FGFR1 and cancer: Collectively, our findings suggest that activation of FGFR1 signaling is a mechanism underlying resistance to targeted therapy in FGFR1high and FGF2high cancer cells, and the addition of FGFR-TKIs to targeted therapy effectively suppresses the development of not only DTP cells but also resistance cells from treatment-naïve cancer in FGFR1high and FGF2high cancer, regardless of tissue origin or driver oncogenes.